Given the prevalence of ESR1-MUT, its intrinsic link with the processes driving HR-positive breast cancer, and its large impact on outcomes of a variety of therapies, ongoing trials should stratify patients by ESR1-MUT status. This evidence concerns the gene ESR1 and breast cancer.